Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_001375505.1(MAP2):āc.364G>Cā(p.Ala122Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000623 in 1,445,072 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
MAP2 (HGNC:6839): (microtubule associated protein 2) This gene encodes a protein that belongs to the microtubule-associated protein family. The proteins of this family are thought to be involved in microtubule assembly, which is an essential step in neurogenesis. The products of similar genes in rat and mouse are neuron-specific cytoskeletal proteins that are enriched in dentrites, implicating a role in determining and stabilizing dentritic shape during neuron development. A number of alternatively spliced variants encoding distinct isoforms have been described. [provided by RefSeq, Jan 2010]
Uncertain significance, criteria provided, single submitter
clinical testing
Ambry Genetics
Apr 05, 2023
The c.364G>C (p.A122P) alteration is located in exon 5 (coding exon 2) of the MAP2 gene. This alteration results from a G to C substitution at nucleotide position 364, causing the alanine (A) at amino acid position 122 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Gain of glycosylation at A122 (P = 0.0582);Gain of glycosylation at A122 (P = 0.0582);Gain of glycosylation at A122 (P = 0.0582);Gain of glycosylation at A122 (P = 0.0582);Gain of glycosylation at A122 (P = 0.0582);Gain of glycosylation at A122 (P = 0.0582);.;